Identifying new targets in leukemogenesis using computational approaches

Archana Jayaraman1, Kaiser Jamil2, Haseeb A Khan3

  • 1Centre for Biotechnology and Bioinformatics, School of Life Sciences, Jawaharlal Nehru Institute of Advanced Studies (JNIAS), Secunderabad, Telangana, India ; Center for Biotechnology, Jawaharlal Nehru Technological University (JNTUH), Kukatpally, Hyderabad, Telangana, India.

Insights

Researchers identified novel drug targets for childhood Acute Lymphoblastic Leukemia (ALL) by analyzing gene expression data. This study proposes five new signature genes, including SMAD2 and CDK9, as potential therapeutic targets and biomarkers for ALL.

Area of Science:

  • Oncology
  • Bioinformatics
  • Genetics

Background:

  • Acute Lymphoblastic Leukemia (ALL) is a common childhood cancer requiring novel therapeutic targets.
  • Understanding ALL's molecular biology is crucial for developing new treatments.
  • Current therapeutic strategies necessitate the identification of new drug targets.

Purpose of the Study:

  • To identify novel genes as potential therapeutic targets for Acute Lymphoblastic Leukemia (ALL) using in silico methods.
  • To discover new biomarkers for prognosis and diagnosis in ALL.
  • To investigate the role of specific genes in leukemogenesis.

Main Methods:

  • Utilized the Oncomine database to retrieve the top 10% overexpressed genes in ALL.
  • Employed prioritization tools (ENDEAVOUR, DIR, TOPPGene) to shortlist candidate leukemogenic genes.
  • Constructed a STRING functional association network and analyzed it with cytoHubba for hub gene identification.

Main Results:

  • Identified SMAD2 and CDK9 as novel hub genes not previously implicated in leukemogenesis.
  • Confirmed the role of MEN1, HDAC1, and LCK in leukemogenesis.
  • Reported five additional signature genes in leukemogenesis for the first time.

Conclusions:

  • Proposed SMAD2, CDK9, MEN1, HDAC1, and LCK as novel therapeutic targets for ALL.
  • Suggested these identified genes as potential biomarkers for ALL prognosis and diagnosis.
  • Highlighted the potential for developing new targeted therapies and improving patient outcomes in ALL.